Skip to content

CLINICAL EVALUATION OF SEENTHIL CHOORANAM AND PANJARATHINA KALIMBU FOR THE MANAGEMNET OF PUZHUVETTU IN CHILDREN

CLINICAL EVALUATION OF SEENTHIL CHOORANAM (INTERNAL) AND PANJARATHINA KALIMBU (EXTERNAL) FOR THE MANAGEMNET OF PUZHUVETTU (ALOPECIA AREATA) IN CHILDREN

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025978
Enrollment
30
Registered
2020-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified

Interventions

Intervention1: Seenthil chooranam(Internal) Panjarathina kalimbu(External): Seenthil chooranam as powder form,age 5-7 years:500 mg (BD),8-12 years:1 gm(BD) per oral,Adjuvant:sarkarai,Duration: 45 day

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Hair loss in patches The area of hair loss may be painful or tingle Non-scarring Scattered long hairs within the bald area Patients who are satisfying minimum of 3-4 symptoms Willing to take photographs whenever required. Patients who are willing to stay in IPD Ward or willing to attend OP Dept. as per schedule. Patientâ??s informant / Parent willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: Scarring alopecia Alopecia universalis Alopecia totalis Vitilogo Atopic dermatitis Thyroid disease Tinea capitis Trichotilomania Any other serious illness

Design outcomes

Primary

MeasureTime frame
Efficacy of the trial drug is measured by SALT SCORE with Alopecia areata in childrenTimepoint: 18 MONTHS

Secondary

MeasureTime frame
Reduction in the remission of the disease and improvement in the quality of life in childrenTimepoint: 18 months

Countries

India

Contacts

Public ContactDr M Meenakshi Sundaram

National Institute of Siddha

drsureshherbal@gmail.com9962571137

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026